New drug cuts muscle loss in spinal muscle disease
A newly approved drug is the first to directly target the mechanism behind muscle wasting in spinal muscular atrophy. And the underlying biology connects to how muscles age more broadly.
Spinal muscular atrophy (SMA) is a rare condition in which nerve cells in the spinal cord deteriorate and muscles progressively weaken. Existing therapies target the SMN2 gene, which helps produce a protein that keeps those nerve cells partly alive. A new drug, Isembyld, takes a different angle: it inhibits myostatin, a protein that actively suppresses muscle growth.
What the trial showed
The US Food and Drug Administration approved Isembyld based on a clinical trial in children and young adults with SMA who were already receiving SMN2-targeting therapy. The researchers report that patients in the Isembyld group improved their motor skills after one year, while those in the placebo group declined. That difference was statistically significant.
The drug is approved for adults and children aged two and older who are already using an SMN2-targeting therapy. The combination appears more effective than either treatment alone.
Relevance for ageing
Myostatin inhibition as a concept has long interested researchers trying to counter age-related muscle loss (sarcopenia). As people age, muscle mass declines, partly because the system that suppresses muscle growth becomes increasingly dominant. Whether myostatin inhibition is also safe and effective in ageing without muscle disease is a separate question that has not yet been answered clinically.
The approval of Isembyld does demonstrate that myostatin inhibition can be clinically effective in humans. That is a proof of concept relevant to broader applications in muscle research. Caution remains warranted: SMA patients are not a representative model for normal ageing.
Search terms to explore further: myostatin inhibition muscle preservation ageing | spinal muscular atrophy SMN2 combination therapy | sarcopenia myostatin clinical trials